Peptides like GLP-1 account for 31 of 370 new drugs approved by the US FDA between 2016 and 2023.

Diabetes drug GLP-1 is a peptide (that's what the 'P' is for)

Glucagon-like peptide-1, or GLP-1, is one of the most well-known peptides in common use. In 2024, 26.5% of all adults with diagnosed diabetes used the substance. GLP-1 was particularly popular among people with diabetes aged 50-64, followed by younger adults and then seniors aged 65+.

The US FDA defines peptides as being 40 amino acids or less

The US Food and Drug Administration regulates these short strings of amino acids as drugs and approves them for commercial use. These products may be produced naturally or synthesized via medicinal chemistry for therapeutic use.

GLP-1 drugs are under investigation for treating Alzheimer's, Parkinson's, and drug addiction

Researchers are investigating GLP-1 applications for a variety of chronic conditions. One area of interest stems from how study participants using GLP-1 for diabetes and obesity reported describing less longing for wine and cigarettes while taking the medication—intriguing researchers about using the drugs for addiction applications. The drug, they theorize, could bind to receptors that mediate desire. (Some users may experience a paywall.)

GLP-1s are netting interest for treating autoimmune diseases, but are considered experimental

Already used to treat type 2 diabetes, the novel medications are showing some early promise in experimental studies at reducing inflammation and treating autoimmune conditions including rheumatoid arthritis and inflammatory bowel conditions. But researchers caution that side effects are still under investigation—rarely the medication has caused lupus, an autoimmune disease.

Tirzepatide: A GLP-1 drug that also acts on separate receptors to promote weight loss

Tirzepatide, like semaglutide, is a GLP-1 drug used in diabetes treatment and for weight loss. Unlike semaglutide, it also acts on glucose-dependent insulinotropic polypeptide receptors, proving a second route to reducing appetite as a means to treat diabetes and promote weight loss.

See which GLP-1 drugs are currently approved (along with their cost)

Around 75% of prescriptions for GLP-1 drugs are used to treat diabetes, while the remainder is used for weight loss. This overview from GoodRX includes a list and overview of currently available options along with prices for each.

Food companies are exploring 'GLP-1 friendly' diet labels

Producers of foods like Healthy Choice frozen meals are placing "GLP-1 friendly" labels on their food, but there's no regulation about what that label means. Nutritionists say that GLP-1s can help reduce appetite, but healthy, balanced diets are a necessary complement to the medications. Data shows that about half of GLP-1 users quit these medications within a year and then rapidly regain weight, underscoring the importance of also prioritizing healthy eating.

Peptide research dates back to the late 1800s

Peptide science dates back to the late 1800s with some early peptide synthesis work, but peptides took off in the medical sphere after surgeon Frederick Banting and his colleague's isolation of insulin from dog pancreases in 1921.

The US FDA issued a 2025 warning about BPC-157 and other popular peptides

BPC-157, which mimics a naturally occurring gut peptide involved in soft tissue repair, has been marketed for various regenerative properties. But the FDA warned in July 2025 that it doesn't have enough data to assess its safety in humans and that such products may also pose risks related to contamination.

Telehealth demand for GLP-1s is on the rise as people seek it out for myriad reasons—the proportion of non-obesity and non-diabetes-related prescriptions for the drug soared from 4.5% in 2018 to 17% in 2023.

In 2023, Americans spent more than $50B on weight loss drugs, a number expected to triple or more by the end of the decade.

Medicare does not pay for GLP-1 for obesity

Coverage for GLP-1s for obesity treatment is limited. It's barred under Medicare, and it's only covered under Medicaid in 13 states as of January 2026, since states can choose whether to cover weight-loss drugs under Medicaid. Coverage with private insurers also remains limited.

GLP-1 drugs, first used to manage diabetes, were derived from Gila monster saliva

Scientists studying the barely-there feeding frequency of the Gila monster found its saliva had a hormone regulating blood sugar and appetite. Further research revealed this hormone resembled a human one known as GLP-1, giving rise to the modern wave of diabetes and weight-management drugs.

Peptide TB-500, promoted for regenerative healing, is not FDA approved

Watch a board-certified sports medicine therapist detail his thinking about this synthetic peptide; he says it's "promising but unproven." He notes that this product is designed to mimic the natural protein thymosin beta-4, found in human and animal tissues, which promotes wound healing. TB-500 is classified as a research peptide for recovery, meaning it's not approved for human use and has not yet undergone rigorous human trials on its safety and efficacy.

When people stopped using GLP-1, they regained two-thirds of the weight back

Research from 2022 found that when people stopped using the injectable form of the medication, they regained up to two-thirds of lost weight within a year. The finding suggests ongoing treatment will be required for weight loss.

The lack of guidance on getting off GLP-1s leaves patients at risk

Dr. David Kessler, former FDA Commissioner and public health leader, explores how these drugs override the brain’s reward-driven eating habits but have notable side effects. These include developing eating disorders, muscle loss, and intestinal obstruction.

Peptides may have predated ribosomes—the cell's protein factory

Some scientists have hypothesized that peptides and RNA molecules may have coevolved as a single, mixed "chimeric" molecule, fueling the beginning of protein production and predating a primitive version of the ribosome. All life today uses ribosomes to make peptides. (Some users may experience a paywall.)

FDA approved the first ever peanut allergy treatment in January 2020

This new medication, called Palforzia, is designed to stave off severe reactions from accidental peanut exposures with a daily dose that is increased over time under an allergist’s supervision. It’s not a treatment that should be administered during an allergic reaction, however. Epinephrine, usually administered via injection, remains the intervention for severe reactions.

US FDA recently approved the first new schizophrenia drug in decades

Though other antipsychotics block dopamine receptors, a new drug, Cobenfy, influences dopamine levels via a different pathway—it stimulates a pair of specialized receptors in the brain that control the release of a substance called acetylcholine. This alternative approach may help patients avoid serious side effects like weight gain. (Some users may experience a paywall.)

How semaglutides are both better and worse than we know

The drugs were developed for use treating diabetes and, later, weight loss, but they have proven helpful with the heart, kidneys, and colon. On the flipside, it may slow digestion and lead to gastroparesis, or stomach blockages, and unexpected babies resulting from the slow effect of birth control pills.

Two festival-goers were hospitalized after receiving peptide injections, raising questions

Investigative journalism shop ProPublica wrote about two people who became extremely ill following antiaging peptide injections. Authorities were examining whether the individuals were sickened by an infection, contamination related to the injections, or an issue with the medication itself, according to documents obtained by the journalists at ProPublica.

Hormone and peptide compounds imported from China soared in 2025

US customs data indicates that these imports doubled to $328M in the first three quarters of 2025, from $164M in the same period of 2024. The imports include GLPs, among other products. (Some users may experience a paywall.)

In 2015, the FDA approved the first 3D-printed prescription tablet

Spritam, an epilepsy medication, had been too large and difficult to swallow, particularly due to its inability to dissolve easily. The new pill was designed with porous layers to enhance its dissolvability, paving the way for future 3D printing of drugs.

Mice were able to regenerate retinal cells in the lab—a breakthrough for mammals

Using gene therapy, a team of Korean researchers has enabled retinal regeneration in mice by blocking the intercellular transfer of a single inhibitory protein. This 2025 finding creates a new potential direction for treating retinal diseases. The work, which is still in animal studies, is projected to enter early-stage clinical trials in the next few years.

The word peptide comes from Greek

Originating from the Greek term "peptos," which means digestible, peptide as a word refers to two or more amino acids. (Some users may encounter a paywall.)

A new daily MS pill is seeking regulatory approval in 2026

In clinical trials, Roche's fenebrutinib showed promise treating primary progressive MS and doubling relapse-free time in patients with relapsing MS as compared to existing treatment. But some liver damage and two possible drug-related deaths in the trials may make it difficult for the drug to net approval. (Some users may encounter a paywall.)

The US FDA considered mitochondrial replacement therapy during 2014 hearings

An agency committee assessed if this approach could have undesirable ripple effects across multiple generations and whether a clinical trial involving this approach would be appropriate. As of 2026, the US has continued to prohibit this procedure though it is legal in other settings including the UK and Australia.

Remylination is a huge focus for treatment—especially among older adults

Our ability to build new myelin sheaths for nerves degrades with age. There have been research advances boosting cells that support these processes and clear away debris from degraded myelin, but not yet any medications to boost myelination itself, which would aid nerve signaling and preserve nerve function.

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

Advanced drugs are closing in on cancer's deadliest mutations

The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.

How Gleevec transformed leukemia treatment and cancer research

An outline of the discovery of imatinib (Gleevec), a ground-breaking drug that transformed the treatment of chronic myelogenous leukemia and sparked the beginning of precision medicine.

Pharmaceutical companies can use ChatGPT to improve drug development

Moderna has incorporated the tool into its workflows to accelerate analysis and identify optimal drug dosage from clinical data. The company's legal team also uses a custom GPT—Contract Companion—to break down and summarize contracts quickly.

Early research suggests CAR-T therapy might treat scleroderma, reducing skin thickening

Clinical data from a couple patients in 2025 indicated that one experimental CAR-T therapy called rese-cel was able to genetically reprogram T cells to eliminate certain problematic immune B cells that were causing the condition. The therapy reduced skin thickening and allowed the patients to halt using immunosuppressive medications and steroids.

Gene therapy treats a disease by editing its DNA source

This modification is typically performed by viruses, which are naturally skilled at entering cells but have their disease-causing component removed before delivery. Once inside, cells can use the inserted genetic material to produce more helpful proteins, fewer harmful ones, or create new proteins.

Restoring vision in impaired patients via CRISPR

Since CRISPR was revealed as a gene editing tool in 2012, it has been on an accelerated track to real-world applications. Among other clinical demonstrations, doctors have now injected a CRISPR treatment directly into eye cells, helping vision-impaired patients see shapes and colors again.

Stem cell therapies

Stem cells' special attributes interest researchers developing new therapeutic tools for a variety of health problems. Much of this research is done with support from the National Institutes of Health (NIH). This page offers a snapshot of research programs funded by the NIH and the health problems those programs focus on.

Biotech is trying to boost drug production efficiency—using chicken eggs

A company called Neion Bio is genetically engineering birds in a bid to produce medical compounds, a herculean task that scientists have struggled with for decades. The US FDA has approved only one chicken-derived drug in the past—an expensive treatment for a rare liver disorder. (Some users may encounter a paywall.)

See different pig-to-human xenotransplantation possibilities

Xenotransplantation can include the insertion of any organ, tissue, cells or fluids from any nonhuman animal into a human. This US Food and Drug Administration graphic about pig-to-human applications shows different possibilities, including the exploration of using pig pancreatic cells for treating diabetes.

Early-onset Alzheimer's can appear as early as age 30

Drugs recently approved to slow the progression of Alzheimer's appear to work best when administered as early as possible. Early stages are marked by a low buildup of tau, a protein experts believe clumps into misfolded, neuron-disrupting tangles once clusters of another protein—amyloid beta—have already started causing damage.

Interface device implanted into ALS patients restored some of their abilities

Most people with amyotrophic lateral sclerosis, or Lou Gehrig's disease, require assistance with daily life due to loss of motor control. The electrode-coated, stent-like device used motor mapping data and machine learning to translate brain activity into actions.

A snapshot of progress in cancer treatments

The American Association for Cancer Research's "Snapshot of a Year of Progress" offers an overview of significant advancements in cancer research and treatment over the past year. Take a quick look at the rapid pace of scientific discovery and the translation of research findings into clinical practice. In 2024 alone, health regulators approved 15 new anticancer therapies alone.

The Armamentarium is a set of new gene therapy tools to fight brain diseases

Research from 29 universities and institutions across North America has resulted in the development of 1,000 tools that provide large-scale, cell-type specific targeting for the first time. These tools may be used to alter the activity of brain cells to address some neurological diseases and sleep disorders.

Bupropion is the only antidepressant approved for the preventive treatment of SAD

Clinical trials showed a 44% reduction in risk for recurrence of SAD for those who took the drug compared to a placebo group. Bupropion is a norepinephrine–dopamine reuptake inhibitor, which increases dopamine (other common antidepressants, known as selective serotonin reuptake inhibitors, sometimes can suppress dopamine, but not always).

Schizophrenia is being studied with pea-sized 'mini-brains'

Brain organoid research is enabling researchers to study distinct electrical firing patterns associated with schizophrenia. These "mini-brains" that are constructed in the lab from patients' cells could lead to better diagnosis approaches and drug development.

Explore an animated list of nine scientific breakthroughs funded by NASA, the NSF, and the NIH

Among the technologies made possible by the National Science Foundation and the National Institutes of Health were the CAPTCHA digital puzzles to block bots from accessing sites, the set of diabetes and obesity drugs that fall under the umbrella of GLP-1 receptor agonists, and various cordless appliances, including the handheld vacuum cleaner. (Some readers may experience a paywall.)

The first prenatal screen for disease was developed in 1961

Scientist Robert Guthrie created a method to test newborns for a metabolic defect called phenylketonuria, or PKU. This blood test didn't look for gene variants—it hunted for excess phenylalanine in the blood. The disorder is caused by an inability to digest the amino acid phenylalanine, leading to excess phenylalanine in the body. PKU results in intellectual disability, seizures, and other symptoms if it isn't caught early and treated with a specialized diet.

An overview of 200 years of diabetes treatment

Diabetes treatment became truly effective after the advent of insulin injections in the early 1900s. Diabetes is becoming increasingly common. Current trends estimate one in three Americans will have diabetes by 2050. This overview explores two centuries of diabetes treatment—starting in 1812—and outline potential challenges to treatment and prevention.

Compounding pharmacies make custom drug formulations during drug shortages

Compounded semaglutide refers to customized versions of the medication prepared by pharmacies, especially during shortages of FDA-approved products like Ozempic and Wegovy. While compounded forms of brand-name medications can make it easier to access the drugs, the quality of such medications often varies.

New drugs called Gepants have been shown to improve the quality of life of many sufferers.

Journalist Eva Wiseman has had migraines since childhood. Beginning with a yawn they segue into visual auras before turning into severe pain. As it so happened, she experienced a migraine during the course of her interview with Dr. Peter Goadsby, a pioneer in understanding and treating migraines as well as getting the world to treat them seriously.

About 250,000 patients accessed assisted reproductive technologies in 2022

In 2022, 251,542 patients tried assisted reproductive technologies—most commonly IVF—resulting in more than 98,000 infants. Those children represent around 2.6% of the babies born in the US.